However, the role of TLR7 and the efficacy of its agonists in NAFLD, which ranges from simple steatosis that can progress to NASH and then to fibrosis or cirrhosis, is unknown. This evidence concerns the gene TLR7 and metabolic dysfunction-associated steatohepatitis.